JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

Glaucoma Unveiled: A Review of Current Treatments and Emerging Therapeutic Advances"

Pankesh Bhagwat Katarnaware, Aditya Kangane, Dr. G. S. Talele

Student, Student, Principal(Guide)

Matoshri college of pharmacy,Eklahre,Nashik

Abstract

Glaucoma remains one of the leading causes of irreversible blindness worldwide, characterized by progressive optic nerve damage often associated with elevated intraocular pressure (IOP). This article provides a comprehensive overview of current pharmacological treatments for glaucoma, with a particular emphasis on common prostaglandin analogues (PGAs), such as latanoprost, bimatoprost, travoprost, and tafluprost. These medications have demonstrated significant efficacy in lowering IOP through various mechanisms of action, making them first-line therapies. However, despite their effectiveness, a considerable proportion of glaucoma patients face challenges with medication adherence. Factors contributing to non-adherence include age-related difficulties, forgetfulness, complex medication regimens, financial constraints, and a lack of understanding about the disease and its treatment.

The review highlights the critical role of patient-physician communication in addressing these adherence barriers. By fostering open dialogue and providing tailored education, healthcare providers can empower patients to recognize the importance of consistent medication use in preventing vision loss. Additionally, the article discusses the impact of emerging treatment modalities, including gene therapy and sustained-release delivery systems, which aim to improve adherence by minimizing the frequency of dosing and enhancing therapeutic efficacy. recent advancements in nanotechnology also present exciting possibilities for revolutionizing ocular drug delivery. Nanoparticles and nanoscale systems can enhance drug penetration, optimize release profiles, and reduce side effects, thereby improving the overall management of glaucoma.

To sum up, ongoing research initiatives are essential for deepening our understanding of glaucoma and improving treatment strategies. By integrating innovative therapeutic approaches with a strong focus on patient education and adherence, we can significantly enhance the quality of life for individuals living with this chronic condition. The future of glaucoma management lies in a multifaceted approach that combines technological advancements with patient-centered care, ultimately aiming to preserve vision and improve outcomes for patients worldwide.

Keywords – glaucoma, blindness, intraocular pressure, prostaglandin analogues (PGAs), selective laser trabeculoplasty, aqueous humour, uveoscleral outflow.

Introduction

Glaucoma, identified as an ocular neuropathy, results in progressive neurodegeneration and vision impairment [1]. It is a condition that damages the optic nerve of the eye and worsens gradually, often associated with increased pressure in the eye [2]. Elevated intraocular pressure can cause damage to the optic nerve, responsible for transmitting images to the brain. If left untreated, glaucoma can lead to permanent vision loss due to continued damage to the optic nerve from high eye pressure. Left untreated, glaucoma can lead to permanent blindness within a few years and is the primary cause of irreversible blindness [3].



Figure 1: Comparison between normal eye vs eye with glaucoma

There are three types of glaucoma: primary, secondary, and congenital. Depending on the anterior chamber angle, these types can be further categorized as "open-angle" and "closed-angle" (or "angle closure") glaucoma. The space between the iris and cornea, known as the angle, is where fluid must pass in order for the trabecular meshwork to open up and allow drainage. When the angle between the cornea and iris is closed, as in the case of closed angle glaucoma, it results in the obstruction of aqueous humor flow. Closed-angle glaucoma can lead to rapid visual loss and is often accompanied by discomfort. Primary open angle glaucoma (POAG) is a common type of glaucoma where the iridocorneal angle is unobstructed. Elevated intraocular pressure (IOP) is one of the primary risk factors for the development of POAG.

Glaucoma is often referred to as the "silent thief of sight" due to the gradual nature of vision loss and the absence of symptoms until the advanced stages. Treatment aims to prevent further vision loss, as the damage is typically irreversible. Globally, glaucoma is the second leading cause of blindness, following cataracts [4]. It affects 1 in 200 people under 50 and 1 in 10 over 80. Early detection of the condition allows for medical and surgical interventions to reduce or halt its advancement.

Figure 2: Types of glaucoma

Types of glaucoma	Description	Causes/Risk factors	Symptoms	Treatment options
Primary open angle glaucoma (POAG)	Most common type; gradual loss of peripheral vision.	Age, family history, elevated IOP.	Often asymptomatic until advanced; peripheral vision loss.	Prostaglandin analogues, laser therapy, surgery.
Angle closure glaucoma	Sudden rise in IOP; can be acute or chronic	Narrow anterior chamber angle, genetics.	Severe eye pain, nausea, headaches, blurred vision, seeing halos.	Immediate medical treatment, laser peripheral iridotomy.
Secondary glaucoma	Occurs due to other conditions or medication.	Eye injuries, inflammation, diabetes, steroids.	Varies; may have similar symptoms to POAG.	Treat underlying condition; medications, surgery.
congenital glaucoma	Present at birth; due to abnormal eye development.	Genetic factors, family history.	Sensitive to light, tearing, eye enlargement.	Surgery to improve drainage; medications.
Normal tension glaucoma	Damage to the optic nerve despite normal IOP.	Unknown; may involve vascular issues.	Similar to POAGs, with gradual vision loss.	IOP lowering medications, surgery if necessary.
Pigmentary glaucoma	Caused by pigment dispersion; typically in young males.	Family history, myopia.	Blurred vision, halos around lights, temporary vision changes.	Medications, laser therapy, surgery if needed.

symptoms

Glaucoma is often called the "sneak thief of sight" due to its lack of initial symptoms. The first indication of glaucoma is a loss of peripheral vision. However, it presents various symptoms including:

- Tearing and dryness-
  Patients may experience chronic dryness or excessive tearing, impacting comfort.

- Itching sensation-
  Persistent itching may lead to discomfort and affect daily activities.

- Blurred or dim vision-
  This can hinder tasks requiring clear sight, such as reading or driving.

- Sensation of something in the eye-
  This sensation can be distracting and uncomfortable.

- Difficulty seeing in daylight-
  Patients may struggle with both bright and dim environments.

Elevated intraocular pressure can lead to severe eye pain, headaches, vision impairment, and the perception of halos around lights.[5]

Causes

Glaucoma is primarily caused by an increase in the pressure inside the eye. This increase results from inadequate circulation of the eye fluid (aqueous humor) in the front part of the eye. Physical or chemical damage to the eye, severe infection, blood vessel blockage, inflammatory diseases, and eye surgery can all be contributing factors to glaucoma. Emotional stress has the potential to impact intraocular pressure, which in turn can lead to glaucoma. This intraocular pressure is also associated with both psychological and physical stress. Glaucoma frequently affects both eyes, although the extent of involvement can vary.[6]

- Genetic predisposition:
  Family history significantly increases the risk of developing glaucoma.

- Environmental influences:
  Lifestyle factors such as poor diet, lack of exercise, and stress can exacerbate risk.

- Physical or chemical damage:
  Trauma or infections can lead to increased pressure.
- Systemic factors:
  Emotional and physical stress have been linked to changes in Iop.

Treatment

The treatment includes some anti glaucoma medications such as eye drops, medication, and eye surgery.

1. Laser therapy-

Selective laser trabeculoplasty (SLT) is the most popular method for increasing conventional aqueous outflow through the trabecular meshwork, surpassing argon laser trabeculoplasty in terms of effectiveness. Despite having similar IOP-lowering effects, SLT is less damaging to the trabecular mesh-work than argon laser trabeculoplasty [7,8]. Initially recommended for patients who had not responded to medical management (lack of IOP control or intolerance to eye drops), SLT can also be used as a first-line treatment option. It is well tolerated, has few side effects, and can be repeated several times. SLT is effective in about 80% of patients, lowering IOP equivalent to one medication, but has a 50% failure rate at two years [8].

2. Topical treatment-

The mainstay of glaucoma treatment is the IOP-lowering eye drops. Prostaglandin analogues, or PGAs, are the most successful and well-tolerated family of eye drops for reducing intraocular pressure. When taken once daily, they are most effective for a whole day. [9] in addition to having a better safety profile, these characteristics usually make PGAs the preferred choice. [10] by enhancing the drainage of aqueous humor through the uveoscleral outflow pathway, which accounts for 10% of aqueous outflow PGAs that reduce IOP.

Introduction to Prostaglandins

Local hormones known as prostaglandins are a class that contain several receptors and effects. They are involved in many bodily functions, such as dilation and constriction of blood vessels, immune system regulation, and smooth muscle contraction and relaxation. It was initially documented in 1985 how prostaglandins—the tromethamine salt of PGF2—affect the eyes. In 1997, the FDA authorized latanoprost as the first prostaglandin for ocular use. Following in 2001 were bimatoprost and travoprost. 2012 saw the FDA approve tafluprost, the most current prostaglandin to do so. [11]

Mechanism of action

It improves both the trabecular outflow and the uveo-scleral outflow of aqueous humor. It functions by altering the structural composition of matrix metallo-proteinases. As a result, the connective tissue-filled gaps enlarge and the cell shape changes, decreasing resistance and increasing drainage. Prostaglandins can affect aqueous drainage since they have receptors on the TM, ciliary muscle, and sclera.[12]

Classification:

PGAs: Tafluprost (0.0015%), latanoprost (0.005%) and travoprost (0.004%)

Prostamides: bimatoprost (0.03 and 0.01%)

Eicosanoids: unoprostone (0.15%)

Common prostaglandin analogues (PGAs):

1)Latanoprost



Figure 3 latanoprost structure

It is available at a strength of 0.005%. Latanoprost lowers IOP by 30–35% more successfully than timolol. When used with all other anti-glaucoma drugs, its unique manner of action can lower IOP additively.8 Complications include trichomegaly, hyperaemia, and increased iris pigmentation may arise from prolonged usage. Systemic side effects are uncommon. All of these negative consequences are reversible. The hyperemia brought on by the drug is generally gone in two to four weeks. For latanoprost, cold chain maintenance is important. However, latanoprost stable at room temperature is a relatively new product.[13]

2)Bimatoprost



Figure 4 bimatoprost structure

It is prostamide's analogue. The amide ester that is attached to the carboxyl group at the end of the carbon chain gives it its unique structure. The strengths that are offered are 0.03 and 0.01%. Like other PGAs, it increases uveo-scleral outflow but also acts on prostamide receptors in the trabecular meshwork to influence conventional outflow. The reason that IOP is regulated can be understood by contrasting this dual action with that of other prostaglandins and the combination of timolol and brinzolamide. In terms of monotherapy for glaucoma, it is the most successful medicine. When compared to other prostaglandins, hyperaemia is more common. To reduce this side effect, newer formulations of bimatoprost were developed with a drug concentration of 0.01%.[14]

3)Travoprost



Figure 5 travoprost structure

It is a part of the PGF2a analogue group. Unlike other drugs in the same class, it works only agonistically at the receptor location. It is available at a strength of 0.004% and should be taken once day. It's been shown that travoprost alone results in better management of intraocular pressure than does treatment with both dorzolamide and timolol together. By 8 to 9 mm Hg, it can lower the baseline intraocular pressure of 25 to 28 mm Hg. Diurnal fluctuation is very well stabilized by this drug. It functions as an agonist in conjunction with other anti-glaucoma drugs, and a combination therapy can reduce IOP by an extra 5.6 mm Hg. In [14]

4)tafluprost



Figure 6 tafluprost structure

At a potency of 0.0015%, it partly inhibits the PGF2 receptor. Latanoprost and travoprost are similar to MOA. Its greater rate of corneal penetration is attributed to its lipophilic nature. All prostaglandins require 2-4 hours to begin working, 12 hours to reach their maximum impact, and the body may need up to 6 weeks to completely eliminate them when the drug is stopped. Intraocular pressure has decreased from baseline by 25–35%. In [14]

Side effects:

Ocular-burning, stinging, sensitivity to light, hyperemia, blurred vision.

Systemic-headache, flu-like symptoms, hypertension.

Risk factors

1. **Age and family history**
   As individuals age, the likelihood of developing glaucoma significantly rises. Nevertheless, in the normal aging process, there are minimal alterations in the dynamics of aqueous humor flow at a physiological level. Tonography studies have shown that the outflow facility of aqueous humor declines with age. After reaching the age of 40, the risk of developing glaucoma notably increases, especially for those with a family history of the condition [15]. It has been calculated that the probability of having glaucoma is approximately 10 times higher in first-degree relatives of individuals with glaucoma [16].

2. Diabetes

Diabetes can lead to various eye complications, such as retinopathy, cataracts, uveitis, and neovascularization. There is a significant link between diabetes and a higher risk of glaucoma. People without diabetes but with elevated levels of fasting glucose, fasting insulin, HbA1c, and HOMA-IR may also face an increased risk of glaucoma. Several studies have indicated that diabetes may heighten the risk of glaucoma [17]. Many studies have examined the connection between diabetes and glaucoma [18], [19]. Research has also shown that individuals with diabetes have a greater risk of glaucoma compared to those without diabetes, as observed in the Beaver study. The Beaver Dam Eye study, the Blue Mountains Eye study, the Los Angeles Latino Eye Study, and several other population-based studies all observed a higher risk of glaucoma in individuals with diabetes compared to those without diabetes [20], [21].

3. Myopia nearsightedness

Myopia can result in blindness conditions such early cataract development, glaucoma, retinal detachment, and macular degeneration. It is linked to a higher risk of pathological ocular consequences. Numerous wealthy nations have excessive myopia as a primary contributing factor to legal blindness, according to studies. IOP and other glaucoma risk variables were not significant in the two- to three-fold higher risk of glaucoma observed in myopic patients as compared to non-myopic individuals [22].

4. Medication

Drugs such as antidepressants, the two main categories of antidepressants that promote angle closure are serotonin-specific reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Nebulized delivery of bronchodilator drugs, such as α2-adrenergic agonists or anticholinergic pharmaceuticals, has been proposed as a means of effectively absorbing a considerable amount across the conjunctiva and cornea in cases of asthma and chronic obstructive airway disease.The British National Formulary does not distinguish between patients with open-angle glaucoma and angle-closure glaucoma, nor between those who have had prior laser treatment for their occludable anterior chamber angles. Instead, it lists "glaucoma" as a contraindication to the use of anticholinergics for urinary incontinence and antispasmodics. Acute angle closure, or AAC, following general anesthesia has been documented in a number of case series, leading to irreversible vision loss due to glaucomatous optic neuropathy.Many over-the-counter medications for coughs and colds contain ingredients that also have strong sympathomimetic or anticholinergic effects, such as decongestants or antihistamines [23].

5. Diet and glaucoma

The possibility that lifestyle or environmental variables, such food composition, might affect the onset and progression of glaucoma through modifications to retinal ganglion cell apoptosis or by affecting intraocular pressure (IOP) has long piqued curiosity. Ensuring good ocular and visual health is strongly correlated with appropriate diet. Dry eyes, vascular ocular illness, diabetic retinopathy, age-associated macular degeneration, cataract development, and glaucoma formation have all been tied to inadequate, imbalanced, or excessive food consumption. Because glaucoma can be modified by altering eating habits or taking supplements, there is increased interest in the role of dietary variables in the disease [24]. The identification of food variables that alter the risk of glaucoma might be a major preventative strategy as well as a source of information on the etiology of the condition.Considering that dietary intake may be changed, the effects of substances having antioxidant activity are quite interesting. It has been demonstrated that, even in the western world where there is no obvious malnutrition, variations in the consumption of antioxidants can affect how an eye illness (such as age-related macular degeneration) develops [25].

6. Alcohol consumption

A research found that alcohol use of less than 30 grams per day had no effect on the risk of POAG: as compared to non-drinkers, the pooled relative risks (RRs) were 0.99 (95% Confidence Interval [CI]: 0.83–1.19) for drinking less than 10 grams per day, 0.96 (95% CI: 0.76–1.22) for 10–19 grams per day, and 0.95 (95% CI: 0.68–1.33) for 20–29 grams per day. Despite the fact that consuming more than 30 g/day was associated with suggestive inverse connections (RR = 0.71), no significant linear correlations were found (95% CI: 0.49–1.04). Reducing intraocular pressure lowers the likelihood of developing primary open-angle glaucoma (POAG) [26].Family history, hypertension, cigarette smoking, and T353I in the myocilin gene are risk factors for POAG, which was further verified by multivariable logistic regression analysis. On the other hand, research has indicated that alcohol intake has a protective benefit [27].

7. Fat consumption

It has been discovered that a diet heavy in n-6 and low in n-3 polyunsaturated fats is linked to a lower incidence of POAG, especially high-tension POAG. When it comes to the relative tissue concentrations of highly unsaturated n-6 fatty acids, such arachidonic acid, there is a strong negative relationship. An increase in the amount of n-6 fat in the diet increases the availability of n-6 prostaglandins (such prostaglandin F2α), which may assist to keep IOP at levels that are less damaging to the optic nerve and hence less likely to cause POAG. Although prostaglandins have primarily been used as therapeutic agents for glaucoma patients [28], these findings imply that changes in the endogenous production of prostaglandins or variations in the physiologic concentrations of these molecules in the eyes of healthy individuals may be associated with an increased risk of developing glaucoma [29].

Introduction to Nanotechnology in ophthalmology-

The goal of nanomedicine is to provide medicinal benefits by using nanostructures and devices that function massively in parallel at the unit cell level to monitor, regulate, build, repair, defend, and enhance human biological systems at the molecular level. Artificial intelligence and biomimicry are two examples of how nanotechnology principles are used in nanomedicine. Theragnostics, oxidative stress management, intraocular pressure measurement, choroidal new vessel treatment, scar prevention following glaucoma surgery, gene therapy for retinal degenerative disease treatment, prosthetics, and regenerative nanomedicine are a few uses of nanotechnology in ophthalmology. Nanotechnology will transform the existing therapeutic hurdles in drug transport and surgical scarring. It will also aid with numerous unresolved problems, such as sight-restoring treatment for patients with retinal degenerative disease [30]. It is anticipated that this developing sector will provide treatments for eye ailments. It has been possible to effectively treat severe evaporative dry eye with a new nanoscale dispersed eye ointment (NDEO) [31]. As in typical eye ointment, petrolatum and lanolin were employed as excipients in semi-solid lipids.

These phases were combined with medium-chain triglycerides (MCT) as a liquid lipid, and both phases were then dispersed in polyvinylpyrrolidone solution to generate nanodispersion. The ointment matrix was entrapped in the MCT nano emulsion, with a mean particle size of around 100 nm, according to a transmission electron microscopy. When compared to commercial polymer-based artificial tears (Tears Natural® Forte), the improved formulation of NDEO showed no cytotoxicity to human corneal epithelial cells and remained stable when kept for six months at 4°C. The evaluation of NDEO's therapeutic effects revealed therapeutic improvement and a tendency of favorable association with increased ointment matrix concentrations in the NDEO compositions in contrast to a commercially available product. Histological analysis showed that the NDEO is safe for use in eye care and that it restored the normal morphology of the cornea and conjunctiva.
Current research [32] illustrates how different nanoparticulate systems, such as liposomes, niosomes, nanoemulsions, nanoparticles, dendrimers, and cyclodextrins, can be applied in the field of ocular drug delivery. It also shows how emerging nanotechnology, such as nanodiagnostics, nanoimaging, and nanomedicine, can be used to explore the boundaries of ocular drug delivery and therapy.

Nanotechnology

In the past, several clinical trials have shown that starting with medical treatment is an effective choice for reducing intraocular pressure and preserving vision [33-34]. While the main method of application is through eye drops, ensuring the right local concentration is a significant challenge. Factors such as small eye capacity, limited tissue penetration, removal by tears and blinking, and drainage through the nose can prevent the medicine from reaching a consistent therapeutic level, leading to the need for multiple daily doses and ultimately resulting in poor patient adherence [35-37]. Other studies also indicate that many patients waste a lot of the eye drops due to incorrect application techniques [36-38]. The absorption of the medication into the bloodstream may cause adverse effects [39-40]. Therefore, efforts are being made to develop improved drug delivery systems, such as eye inserts, smart hydrogels, vesicular and particulate carriers.

Nanoscale drug delivery systems offer the benefits of targeted tissue penetration, improved release kinetics, and enhanced local distribution [41-43]. In the field of tissue engineering and regenerative medicine, nanostructures at the biological scale promote significant interactions for tissue repair and regeneration [42]. The term "nano" was originally defined for the semiconductor industry as having at least one dimension less than 100nanometers. However, the definition of "nano-" has been redefined in an operational manner, with many authors including biologically relevant length scales, such as larger macromolecules and organelles, in the fields of nanobiotechnology and nanomedicine [41-43]. Below, we outline the recent advancements in nanobiotechnology for managing glaucoma.

Nanotoxicity

Nanoparticles may generate cellular toxicity through oxidative stress, interaction with the cell membrane, and inflammation [44]. In contrast to chemical toxicity, where compound purity and drug concentration are the essential determinants, in nanotoxicity other characteristics should be taken into account, such as nanoparticle size, surface shape, and ionic charge [45]. In addition, there are a few toxicity forms that may be independent of the drug delivered, namely particle toxicity, excipient toxicity, contaminant toxicity, and inflammatory toxicity [44]. Each one must be independently investigated in vitro and in vivo.

Specific literature about the toxicity of therapeutic nanoparticles in the eye remains scarce [44]. Nanotoxicity is a subject of key importance to be determined in conjunction with the therapeutic potential of each nanoparticle [46, 47], particularly for those that require repeat-dose regimens [48]. All nanoparticles proposed to be utilized for therapeutic purposes must be thoroughly investigated in terms of local and systemic toxicity, before obtaining the full regulatory approval.

Patients adherence

1. **Patients adherence to a medication regimen-**

Many people fail to take their prescribed drugs as directed, despite data supporting the therape utic value of following a prescribed regimen.Research has revealed six common medicationta king pattern among patients with chronic conditions: roughly onesixth adhere to a regimen nea rly perfectly; one-
sixth take nearly all doses but exhibit some timing irregularities; onesixth miss a single daily d ose occasionally and exhibit some timing irregularities; onesixth take drug holidays three to fo ur times a year with occasional dose omissions; onesixth have a drug holiday monthly or mor

e frequently, with frequent dose omissions; and onesixth take few or no doses while appearing to adhere to a regimen [49].

Since 2459% of glaucoma patients do not experience the full or intended benefit of their treat ment, medication adherence is a major issue in the care of glaucoma patients [51].
The obstacles to sticking to a glaucoma treatment plan are multifaceted, and patients with glau coma differ greatly in how they take their topical treatments.
Patients are reluctant to confess to nonadherence because they innately desire to please their d octors [49].

The majority of glaucoma patients are elderly persons with intrinsic difficulties taking any me dicine; the most prevalent reasons given for this dependence are poor eyesight and issues with motor dexterity [52]. Anti-glaucomatous therapy adherence is hampered by a number of factors, according to Lacey et al. : inadequate application technique training, forgetting drops, scheduling drops incorrectly, and issues with drop supply.

The primary driving force behind adherence seems to be the preservation of one's vision. As a result, it seemed that most people continued to administer drops in spite of these problems bec ause they either believed that drop efficacy would preserve their vision or because they alread y experienced symptoms of visual loss [53].
Few research has looked on how people keep their prescription medications at home.
According to one study, over half of elderly individuals follow general drug storage guidelines , and over half of medications that need to be refrigerated were not [54] kept in the recommen ded manner.
We are aware that glaucoma medication does not need to be refrigerated, but we speculate that this could have contributed to a decreased rate of treatment compliance.

The following variables were most frequently mentioned as potential compliance barriers in th e Glaucoma Adherence and Persistency Study: expense (55%), forgetfulness (32%), fear or de nial (16%), lack of knowledge regarding glaucoma (16%), and regimen complexity (15%).
The doctors believed that the following were the most significant obstacles: patients' lack of d esire to use drops (50%), patients' ignorance of glaucoma (41%), patients' incapacity to explai n the significance of compliance (15%), and patients' short visit duration (12%).
Furthermore, the research distinguished three categories of medical professionals based on beh avioral and attitude variables: idealistic (16%), sceptical (44%), and reactive (41%).

The reactives had the lowest likelihood of anticipating and addressing nonadherence.
Because they did not think they could alter the patient's drug adherence, the skeptics were less likely to talk to the patient about glaucoma or the significance of therapy before starting it.
When they sensed nonadherence, they were more likely to try to comprehend and adhere to concepts that were significant to the patient [55]. When people do not take their medications as directed, they run the danger of not getting the desired effect, which can have detrimental effects including the disease getting worse and overall healthcare costs going up. Therefore, it is critical for patients and physicians to comprehend the aspects involved in sticking to a drug plan.

2. Method of measuring adherence

The doctor must identify non-adherence and determine that the patient's attitude toward glaucoma therapy needs to be addressed before attempting to modify the patient's attitude. Since Hippocrates' day, patients have had their drug regimens observed. Even now, measuring patient adherence is crucial for effectively managing patients with low adherence. There are two types of adherence measurement techniques: direct and indirect techniques. Each has benefits and drawbacks. It is necessary to monitor adherence in glaucoma patients using a gold standard approach, although one has not yet been developed. Directly witnessed therapy, which has the highest accuracy, and blood drug concentration measurement are examples of direct techniques of monitoring adherence.

The direct methods can be laborious for the ophthalmologist, costly assays are needed, and patient distortion is a possibility [50]. The collection of patient questionnaires or self-reports, asking the patient to keep a medication diary, asking the patient how simple it is to apply the prescribed medication, evaluating clinical response, finding out how often prescriptions are refilled, using electronic medication monitors, and evaluating the adherence of younger or older patients by having a caregiver assist are examples of indirect methods of measuring adherence. Simple and rather easy procedures, such as verbal questioning of the patient, questionnaires, and patient diaries, can be modified by the patient [50]. Patients may suppress information regarding non-adherence because they do not want their doctors to think that they are misbehaving.

Encouraging the patient to engage in a partnership with the doctor, founded on valuing the patient's opinions, concerns, and preferences, is one potential answer. As a result, a good patient is someone who collaborates with the doctor to get over practical obstacles to adherence and the unavoidable worries about medication [56, 57]. Ophthalmologists can achieve this by using self-reported adherence measures, such as glaucoma therapy adherence surveys, which evaluate the patient's confidence in medication adherence as well as their understanding of their medical regimen and what they know about it [57]. Self-reported measures might be the most straightforward and economical way for healthcare professionals to assess the non-compliance rate, help better understand the reasons behind and barriers to glaucoma medication adherence, and look into potential ways to increase adherence [53, 58].

3. Questionaries

By asking patients about their motives for starting treatment, whether they have encountered any side effects from their eye drops, or why they are taking their medication, questionnaires are a helpful tool for revealing poor adherence to glaucoma therapy [50]. In order to determine what motivates patients to continue taking their glaucoma medication, Lacey et al. conducted a qualitative research study based on a patient interview. The interview comprised questions about the therapy, memory and regimen for taking the eye drops, medication issues, reasons for using the eye drops, and suggestions from the patients for improving future adherence.

The authors documented impediments to adherence that stemmed directly from the experiences of the participants, including a want for better education delivery that focused on drop application procedures and the repercussions of noncompliance. In order to increase their confidence in adherence, patients also suggested getting regular feedback regarding drop efficacy. Finding a convenient place to apply the drops during the day, forgetting to apply them, or not having enough time to administer them while at work were among the practical difficulties that many patients reported experiencing when answering the adherence questions [53]. They also revealed that many patients had problems with drop application methods.

However, as the interval between visits lengthens, this strategy becomes more error-prone. The patient can readily manipulate the results, which typically causes the patient to overestimate their level of adherence [50].

A few studies compared the validity of self-reported measures with more controllable measurements in glaucoma patients, such as electronic monitoring devices or pharmacy records, and found that the former tended to overvalue the timing and dosages taken (adherence to glaucoma medicine) [58]. Sayner et al. therefore advanced the idea that ophthalmologists may need to employ a cautious and comforting approach when speaking with patients in order to identify potential problems with applying drops on time, ensuring their comfort, and ultimately aiding in the identification of poor adherence (e.g., "I understand that it must be difficult to take your medication on a regular basis"). When was the last time you neglected to take your drops? [50, 58].

4. Patients-physician communication

Carpenter et al. investigated whether patient-physician communication boosts glaucoma patients' medication self-efficacy and found that it can enhance treatment adherence. Providers ought to use a patient-centered approach, spending time getting to know their patients' chronic conditions and finding out how they feel about the course of therapy. Additionally, the study found that patients should receive greater support to address adherence hurdles as they may be less confident in their ability to follow their glaucoma regimen if they ask more questions about medications [59].

In a study of 279 glaucoma patients who had their visits videotaped, it was found that while patient education about their condition occurred during about two thirds of the visits, it had no significant impact on patients' timely take-home of their prescribed medication during the post-visit period. Rather, the sole provider communication component that was found to be substantially correlated with adherence was education regarding the administration of the eye drops. As a result, medical personnel need to support patients' need for a complete awareness of glaucoma by dedicating more time to patient education [60]. An intervention program that included teaching and a reminder system was the subject of an observational research. For patients whose baseline drop-taking was less than 75%, the adherence rate to glaucoma treatment increased from 54% to 73%. The improvement started right away and persisted for three months. According to the research, the likelihood that the treatments altered medication use was increased when a multidimensional approach was used.

The study was unable to identify the most beneficial components of the intervention or the tactics that can be used in clinical settings. Furthermore, the researchers discovered that white patients and those with the lowest baseline adherence showed the greatest improvement in adherence. Furthermore, there was no correlation observed between the improvement in adherence and the IOP level assessed in the clinic. To this purpose, the results of the study demonstrated that many nonadherent patients had satisfactory IOP at routine visits and hence, IOP measurement was thought to be insufficient for estimating adherence. At last, it was highlighted the need for additional study to differentiate individuals' poor adherence to prevent overdosing and identify the components of the adherence program that were most efficient [61].

5. Medication cost

Numerous studies have shown that most glaucoma office visits do not involve a discussion about the expense of treatment. Healthcare professionals frequently fail to inquire about their patients' issues with the expense of their glaucoma medications. As a result, even though patients may have financial difficulties related to their treatment plan, they seldom bring this up with their physicians.

Therefore, in order to enhance adherence from the start of glaucoma therapy, ophthalmologists might think about bringing up the topic of medication expense during office appointments [62]. Giving patients free eye drops could help them get past the financial and physical obstacles of getting drugs. This could be achieved by making the medication refundable or by periodically giving away free samples. Ultimately, over a 60-year period, a cost-utility analysis evaluated the societal costs of optimal versus poor adherence to glaucoma medications among individuals over 40 with newly diagnosed glaucoma. It showed that adherence to glaucoma medications improved quality of life at a relatively small lifetime healthcare cost increase [63].

Emerging treatments

Recent advancements in research are exploring new drug formulations and treatment modalities, including:

- Gene therapy-
  Investigating potential for targeting underlying genetic caused of glaucoma.

- Sustained-released devices-
  Developing methods to deliver medications over extended periods to improve adherence.

Future directions

Ongoing research initiatives aim to enhance understandings of glaucoma and improve treatment strategies for diagnosis and monitoring, such as telemedicine and digital monitoring devices, may revolutionize patient care.

Conclusion

A comprehensive approach that includes pharmacological therapies and places a heavy emphasis on patient adherence to prescribed drug regimens is necessary for the optimal management of glaucoma. Even when there are good treatments available, there can still be substantial obstacles that limit adherence and, ultimately, treatment success, especially when it comes to vulnerable groups like the elderly. Suboptimal medication use is a result of a number of factors, including impaired vision, forgetfulness, and financial difficulties. As a result, healthcare practitioners must implement interventions to improve prescription adherence.

Encouraging honest dialogue between healthcare professionals and patients is crucial for determining and removing each patient's unique adherence hurdles. Patients can feel more empowered and realize how important it is to take their medications consistently in order to preserve their vision if they receive personalized education on the disease and its treatments. Additionally, addressing financial issues by providing samples or having conversations about prescription costs will help to promote adherence. new approaches to treating glaucoma, such as gene therapy and sustained-release medication delivery methods, are particularly promising. These developments may lessen the difficulty of repeat doses and increase patient adherence. Furthermore, new approaches to improving the efficiency and targeting of therapies are provided by the integration of nanotechnology into ocular drug delivery systems, which could completely change the way glaucoma is treated.

As research progresses, reducing the impact of glaucoma will require a multimodal strategy that incorporates cutting-edge therapeutic techniques with patient-centered care. This all-encompassing approach seeks to improve the general quality of life for those with this chronic illness in addition to maintaining vision. In the end, better management and results for glaucoma care can be achieved through the integration of technology, enhanced communication, and customized patient education.

References

[1] Bussel I. and Aref A., Dietary factors and the risk of glaucoma: a review, Ther. Adv. Chronic. Dis. 5(4), 188-194 (2014).

[2] Rhee D. J., Glaucoma. In: Porter RS, Kaplan JL (eds) The Merck Manual Home Health Handbook. (2014), Retrieved November, 2016.

[3] Quigley H. A., Broman A.T., The number of people with glaucoma worldwide in 2010 and 2020, Br. J. Ophthalmol. 90, 262-267 (2006).

[4] Kingman S., "Glaucoma is second leading cause of blindness globally". Bulletin of the World Health Organization. 82(11), 887-888 (2004).

[5] Bhowmik D., Kumar K. P. S., Deb L., Paswan S. and Dutta A. S., Glaucoma -A Eye Disorder Its Causes, Risk Factor, Prevention and Medication, The Pharma. Innov. 1(1), 66-81 (2012).

[6] Casson R. J., Chidlow G., Wood J. P.M., Crowston J. G., Goldberg I., Definition of glaucoma: Clinical and experimental concepts, Clinicl. Experimentl. Ophthalmol. 40(4), 341-349 (2012).

[7] Latina M, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol2002; 14: 94–96.

[8] McAlinden C. Selective laser trabeculoplasty (SLT) vs other treatment modalities for glaucoma: systematic review. Eye 2014; 28:249–258.

[9] Konstas AGP, Topouzis F, Leliopoulou O, et al. 24-hour intraocular pressure control with maximum medical therapy compared with surgery in patients with advanced open-angle glaucoma. Ophthalmology 2006; 114: 761.e1–765.e1.

[10] Stein JD, Ayyagari P, Sloan FA, et al. Rates of glaucoma medication utilization among persons with primary open-angle glaucoma 1992 to 2002. Ophthalmology 2008; 115: 1415–1419.

[11] Winkler NS, Fautsch MP. Effects of prostaglandin analogues on aqueous humor outflow pathways. J Ocul Pharmacol Ther. 2014; 30(2-3):102-9.

[12] Lindnc and Alm, A. prostaglandin Analogues in the treatment of Glaucoma. Drugs and Aging,1999;14(5):387-398

[13] Lee AJ, McCluskey P. Clinical utility and differential effects of prostaglandin analogues in the management of raised intraocular pressure and ocular hypertension. Clin Ophthalmol. 2010; 4:741-64.

[14] Gupta SK, Niranjan D G, Agrawal SS, Srivastava S, Saxena R. Recent advances in pharmacotherapy of glaucoma. Indian J Pharmacol. 2008; 40(5):197-208.

[15] Ito and Michael A. W., Genetics and Environmental Stress Factor Contributions to Anterior Segment Malformations and Glaucoma, Yoko. 1064-1069 (2013).

[16] Saxena R., Singh D., Vashist P., Glaucoma: An emerging peril. Ind J of Community Med. 38, 135-137 (2013).

[17] Zhao D., Cho J., Kim M. H., Friedman D., Guallar E., Diabetes, Glucose Metabolism, and Glaucoma: The 2005–2008 National Health and Nutrition Examination Survey PLoS ONE. 9(11), e112460. doi:10.1371/journal.pone.0112460 (2014).

[18] Howard D.L., Kim M.M. and Hartnett M.E., Predicting glaucoma diagnosis in an elderly sample: revisiting the established populations for epidemiologic studies of the elderly, J. Natl. Med. Assoc. 103, 332–341 (2011).

[19] Tan G.S., Wong T.Y., Fong C.W. and Aung T., Diabetes, metabolic abnormalities, and glaucoma, Arch. Ophthalmol. 127, 1354–1361 (2009).

[20] Newman-Casey P. A., Talwar N., Nan B., Musch D. C. and Stein J.D., The relationship between components of metabolic syndrome and open-angle glaucoma, Ophthalmology. 118, 1318–1326 (2011).

[21] Wise L.A., Rosenberg L., Radin R.G., Mattox C. and Yang E.B., A prospective study of diabetes, lifestyle factors, and glaucoma among African-American women, Ann. Epidemiol. 21, 430–439 (2011).

[22] Chen S. J., Lu P., Zhang W. and Lu J., High myopia as a risk factor in primary open angle glaucoma, Int. J. Ophthalmol. 5(6), 750–753 (2012).

[23] Subak-Sharpe I., Low S., Winifred N. and Paul J., Foster Pharmacological and environmental factors in primary angle-closure glaucoma, Br. Med. Bull. 93(1), 125-143 (2010).

[24] Pasquale L. R. and Kang J. H., Lifestyle, nutrition, and glaucoma, J. Glaucoma. 18(6), 423–428 (2009).

[25] Rehak M., Fric E. and Wiedemann P., Lutein and antioxidants in the prevention of age-related macular degeneration. Ophthalmol. 105(1), 37– 45 (2008).

[26] Kang J. H., Willett W. C., Rosner B. A., Hankinson S. E. and Pasquale L., Prospective Study of Alcohol Consumption and the Risk of Primary Open-Angle Glaucoma, J. Ophthalmic. Epidemiol. 14(3), 337-340 (2007).

[27] Fan B. J., Leung Y. F., Wang N., Lam S. C., Liu Y., Tam O. S. and Pang C. P., Genetic and environmental risk factors for primary open-angle glaucoma, Chinese. Med. J. 117(5), 706-710 (2004).

[28] Mozaffarieh M. and Flammer J., A novel perspective on natural therapeutic approaches in glaucoma therapy, Expert. Opin. Emerg. Drugs. 12(2), 195–198 (2007).

[29] Kang J. H., Pasquale L.R., Willett W.C., Rosner B.A., Egan K.M., Faberowski N. and Hankinson S.E., Dietary fat consumption and primary open angle glaucoma, Am. J. Clin. Nutr. 79, 755–764 (2004).

[30] Zarbin MA, Montemagno C, Leary JF, Ritch R (2013) Nanomedicine for the treatment of retinal and optic nerve diseases. Curr Opin Pharmacol 13: 134148.

[31] Zhang W, Wang Y, Lee BT, Liu C, Wei G, et al. (2014) A novel nanoscale dispersed eye ointment for the treatment of dry eye disease. Nanotechnology 25: 125101.

[32] Sahoo SK, Dilnawaz F, Krishnakumar S (2008) Nanotechnology in ocular drug delivery. Drug Discov Today 13: 144-151.

[33] M. A. Kass, D. K. Heuer, E. J. Higginbotham, et al., (For the Ocular Hypertension Treatment Study Group), "A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma," Archives of Ophthalmology, Vol. 120, No. 6, 2002, pp. 701-713.

[34] L. J. Katz, W. C. Steinmann, A. Kabir, et al., "Selective Laser Trabeculoplasty versus Medical Therapy as Initial Treatment of Glaucoma: A Prospective, Randomized Trial," Journal of Glaucoma, Vol. 21, No. 7, 2011, pp. 460-468.

[35] N. M. Davies, "Biopharmaceutical Considerations in To- pical Ocular Drug Delivery," Clinical and Experimental Pharmacology and Physiology, Vol. 27, No. 7, 2000, pp. 558-562.

[36] T. Tsai, A. L. Robin and J. P. Smith III, "An Evaluation of How Glaucoma Patients Use Topical Medications: A Pilot Study," Transactions of the American Ophthalmological Society, Vol. 105, 2007, pp. 29-33.

[37] C. M. Olthoff, J. G. Hoevenaars, B. W. van den Borne, et al., "Prevalence and Determinants of Non-Adherence to Topical Hypotensive Treatment in Dutch Glaucoma Pa- tients," Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 247, No. 2, 2009, pp. 235-243.

[38] R. Gupta, B. Patil, B. M. Shah, et al., "Evaluating EyeDrop Instillation Technique in Glaucoma Patients," Jour-nal of Glaucoma, Vol. 21, No. 3, 2012, pp. 189-192.

[39] F. C. Hugues and C. Le Jeunne, "Systemic and Local Tolerability of Ophthalmic Drug Formulations. An Up-date," Drug Safety, Vol. 8, No. 5, 1993, pp. 365-380.

[40] R. F. Wang, D. J. Gagliuso and S. M. Podos, "Effect of Flunarizine, a Calcium Channel Blocker, on Intraocular Pressure and Aqueous Humor Dynamics in Monkeys,"Journal of Glaucoma, Vol. 17, No. 1, 2008, pp. 73-78.

[41] O. M. Koo, I. Rubinstein and H. Onyuksel, "Role of Nanotechnology in Targeted Drug Delivery and Imaging: A Concise Review," Nanomedicine, Vol. 1, No. 3, 2005,pp. 193-212.

[42] P. Nguyen, M. Meyyappan and S. C. Yiu, "Applicationsof Nanobiotechnology in Ophthalmology—Part I," Oph-thalmic Research, Vol. 44, 2010, pp. 1-16

[43] R. A. Petros and J. M. DeSimone, "Strategies in the De-sign of Nanoparticles for Therapeutic Applications," Na-ture Reviews Drug Discovery, Vol. 9, 2010, pp. 615-627

[44] Prow TW. Toxicity of nanomaterials to the eye. Wiley Interdiscip Rev Nanomed Nanobiotechnol.2010;2(4):317–33.

[45] Voigt N, Henrich-Noack P, Kockentiedt S, et al. Toxicity of polymeric nanoparticles in vivo and in vitro. J Nanopart Res. 2014;16(6):2379.

[46] De Matteis V, Rinaldi R. Toxicity assessment in the nanoparticle era. Adv Exp Med Biol. 2018;1048: 1–19.

[47] El-Ansary A, Al-Daihan S, Bacha AB, et al. Toxicity of novel nanosized formulations used in medicine. Methods Mol Biol. 2013;1028:47–74.

[48] De Jong WH, Van Der Ven LT, Sleijffers A, et al.Systemic and immunotoxicity of silver nanoparticles in an intravenous 28 days repeated dose toxicity study in rats. Biomaterials. 2013;34(33):8333–43

[49] Budenz, D.L. A Clinician's Guide to the Assessment and Management of Nonadherence in Glaucoma. Ophthalmology 2009, 116, S43–S47.

[50] Osterberg, L.; Blaschke, T. Adherence to Medication. N. Engl. J. Med. 2005, 353, 487–497.

[51] Guven, S.; Koylu, M.T.; Mumcuoglu, T. Adherence to glaucoma medication, illness perceptions, and beliefs about glaucoma: Attitudinal perspectives among Turkish population. Eur. J. Ophthalmol. 2021, 31, 469–476.

[52] Windham, B.G.; Griswold, M.E.; Fried, L.P.; Rubin, G.S.; Xue, Q.-L.; Carlson, M.C. Impaired Vision and the Ability to Take Medications. J. Am. Geriatr. Soc. 2005, 53, 1179–1190.

[53] Lacey, J.; Cate, H.T.; Broadway, D.C. Barriers to adherence with glaucoma medications: A qualitative research study. Eye 2008, 23, 924–932.

[54] Vlieland, N.D.; Bemt, B.J.F.V.D.; Bekker, C.L.; Bouvy, M.L.; Egberts, T.C.G.; Gardarsdottir, H. Older Patients' Compliance with Drug Storage Recommendations. Drugs Aging 2018, 35, 233–241.

[55] Gelb, L.; Friedman, D.S.; Quigley, H.A.; Lyon, D.W.; Tan, J.; Kim, E.E.; Zimmerman, T.J.; Hahn, S.R. Physician Beliefs and Behaviors Related to Glaucoma Treatment Adherence. J. Glaucoma 2008, 17, 690–698.

[56] Stevenson, F.A.; Cox, K.; Britten, N.; Dundar, Y. A systematic review of the research on communication between patients and health care professionals about medicines: The consequences for concordance. Health Expect. 2004, 7, 235–245.

[57] Hahn,S.R. Patient-Centered Communication to Assess and Enhance Patient Adherence to Glaucoma Medication. Ophthalmology 2009, 116, S37–S42.

[58] Sayner, R.; Carpenter, D.M.; Blalock, S.J.; Robin, A.L.; Muir, K.W.; Hartnett, M.E.; Giangiacomo, A.L.; Tudor, G.; Sleath, B. Accuracy of Patient-reported Adherence to Glaucoma Medications on a Visual Analog Scale Compared With Electronic Monitors. Clin. Ther. 2015, 37, 1975–1985.

[59] Carpenter, D.M.; Blalock, S.J.; Sayner, R.; Muir, K.W.; Robin, A.L.; Hartnett, M.E.; Giangiacomo, A.L.; Tudor, G.E.; Sleath, B.L. Communication Predicts Medication Self-Efficacy in Glaucoma Patients. Optom. Vis. Sci. 2016, 93, 731–737.

[60] Sleath, B.; Blalock, S.J.; Carpenter, D.; Sayner, R.; Muir, K.W.; Slota, C.; Lawrence, S.D.; Giangiacomo, A.L.; Hartnett, M.E.; Tudor, G.; et al. Ophthalmologist–Patient Communication, Self-efficacy, and Glaucoma Medication Adherence. Ophthalmology 2015, 122, 748–754

[61] Okeke, C.O.; Quigley, H.A.; Jampel, H.D.; Ying, G.-S.; Plyler, R.J.; Jiang, Y.; Friedman, D.S. Interventions Improve Poor Adherence with Once Daily Glaucoma Medications in Electronically Monitored Patients. Ophthalmology 2009, 116, 2286–2293.

[62] Slota, C.; Davis, S.A.; Blalock, S.J.; Carpenter, D.; Muir, K.W.; Robin, A.L.; Sleath, B. Patient-Physician Communication on Medication Cost during Glaucoma Visits. Optom. Vis. Sci. 2017, 94, 1095–1101.

[63] Newman-Casey,P.A.; Salman, M.; Lee, P.; Gatwood, J.D. Cost-Utility Analysis of Glaucoma Medication Adherence. Ophthalmology 2020, 127, 589–598.

Figure references:

Figure no.1-Wolfe Eye Clinic. “Comparison of Normal Eye and Glaucoma Eye.” Wolfe Eye Clinic, 2023.

Figure no.2- Types of glaucoma. (2024). In *Overview of Glaucoma Treatment and Patient Adherence Strategies* (pp. 1-2).

Figure no.3-"The chemical structure of latanoprost is critical for its function (Wikipedia, 2023)."

Figure no.4-"The chemical structure of bimatoprost is critical for its function (Wikipedia, 2023)."

Figure no.5-"The chemical structure of travoprost is critical for its function (Wikipedia, 2023)."

Figure no.6-"The chemical structure of tafluprost is critical for its function (Wikipedia, 2023)."